On October 18, with the completion of the pouring of the last concrete, the life science reagent research and development and production building project of Kingsrui Biotechnology Company located in Nanjing, Jiangsu Province announced the main body was topped off. As a key project in Nanjing, it will efficiently assist the research and development and outsourcing services of biomedical at home and abroad in the future, and help the status of China's biological industry be improved.
main structure capped
It is reported that the total investment of the project is 1 billion yuan and started construction in April 2022. The project covers an area of about 10,000 square meters and has a construction area of 30,200 square meters. After the first phase of the project, a high-standard factory building and central warehouse that can meet scientific research and development and production will be built. Under the influence of the epidemic, Kingsrui and the construction unit carried out strict epidemic prevention and safe construction, which took 6 months to complete the established plan as scheduled.
Kingsrui Life Science Reagent R&D and Production Building Project, and strive to build a life science R&D service platform that integrates general contracting , and promotes the transformation and upgrading of manufacturing to service industry with new technologies. In recent years, innovative biopharmaceuticals has been one of the fastest-growing sub-industry in the pharmaceutical industry and is also a track for major biopharmaceutical companies to participate. The Chinese pharmaceutical industry also urgently needs a life science research and development platform with a general integrated general contracting model, and the construction of this project is in line with the development trend of this industry. This project can maximize the driving role of leading biopharmaceutical companies, enable high-quality development of upstream and downstream of the industrial chain, and deliver "first in class, best in class" to the Chinese pharmaceutical market and even the global pharmaceutical market, so that Chinese patients can use affordable bioinnovative drugs.
Project renderings
As the first biotech company in Nanjing to be listed on the Hong Kong Stock Exchange, Kingsrui is known as the "king of global gene synthesis". It has maintained the first global market share in the field of gene synthesis for a long time. It is also the single champion of the manufacturing industry of the Ministry of Industry and Information Technology of . In recent years, Kingsray has continued to increase its investment in infrastructure construction to better serve more than 200,000 customers around the world. Starting from 2021, Kingsray has successively expanded its production capacity in the United States, Singapore and China, and continues to accelerate the production capacity construction of polypeptide , sgRNA, ssDNA and GMP-grade magnetic beads. In the biopharmaceutical CDMO business, Kingsray's subsidiary Pengbo Biotechnology is China's first CDMO enterprise to lay out a plasmid virus service platform, and is also the first CDMO enterprise in China to realize the single-family production of plasmid workshop and viral vector workshop. It not only has China's largest commercial plasmid GMP factory, but can provide GMP production of in vitro transcription template linearized plasmids for mRNA vaccines. It is also the first lentivirus vector CDMO and China's leading AAV supplier, but also has a stable and high-yield viral vector platform, with outstanding development potential.
Industry insiders believe that after the project is completed and put into use, it will better promote the connection between Chinese biotechnology companies from genes, peptides, protein , antibodies and other life science reagent services to upstream and downstream biopharmaceutical development, and provide high-quality "one-stop" CRO and CMO services, greatly shorten the product research and development cycle, and help China Pharmaceutical seize the high ground of the global biopharmaceutical market.
